本文選題：塞來(lái)昔布 + 氧誘導(dǎo)視網(wǎng)膜病變�。� 參考：《石河子大學(xué)》2017年碩士論文

【摘要】：目的通過(guò)對(duì)大鼠氧誘導(dǎo)視網(wǎng)膜病變(Oxygen-induced retinopathy,OIR)模型進(jìn)行玻璃體腔注射塞來(lái)昔布,探討塞來(lái)昔布在OIR中對(duì)視網(wǎng)膜新生血管的作用及其機(jī)制。方法7d齡SD乳鼠96只隨機(jī)分為6組:Z組:正常組;O組:OIR組;A組:OIR+溶媒對(duì)照組;B組:OIR+塞來(lái)昔布5μg組;C組:OIR+塞來(lái)昔布20μg組;D組:OIR+塞來(lái)昔布80μg組。除Z組在正常環(huán)境飼養(yǎng)外,其余各組乳鼠均建立OIR模型。乳鼠于生后第12天出氧箱后給予玻璃體內(nèi)注射DMSO及相應(yīng)劑量的塞來(lái)昔布,于生后第17天處死,做組織切片HE染色觀察視網(wǎng)膜組織形態(tài)并計(jì)數(shù)突破內(nèi)界膜的血管內(nèi)皮細(xì)胞核數(shù);石蠟切片行免疫組化染色檢測(cè)VEGF蛋白的表達(dá)。結(jié)果HE染色顯示,Z組、O組、A組、B組、C組、D組突破視網(wǎng)膜內(nèi)界膜的血管內(nèi)皮細(xì)胞核數(shù)分別為(0.44±0.18)個(gè)、(30.60±5.36)個(gè)、(28.05±4.68)個(gè)、(19.58±4.58)個(gè)、(10.13±1.93)個(gè)、(7.58±2.68)個(gè);除O組與A組外,各組間差異均有統(tǒng)計(jì)學(xué)意義(均為P0.05),經(jīng)塞來(lái)昔布治療后,突破內(nèi)界膜的血管內(nèi)皮細(xì)胞核明顯減少,且與劑量正相關(guān);免疫組化結(jié)果顯示,Z組VEGF蛋白表達(dá)呈陰性,表達(dá)率為10%,其余各組可見(jiàn)VEGF蛋白的陽(yáng)性表達(dá),O、A組陽(yáng)性表達(dá)較高,陽(yáng)性率分別為90%、86%,表現(xiàn)為棕褐色顆�；驁F(tuán)塊,均高于B組、C組、D組,且后三組的陽(yáng)性表達(dá)依次減低為68%、42%、30%。結(jié)論塞來(lái)昔布能夠有效抑制大鼠OIR模型視網(wǎng)膜新生血管的生長(zhǎng),且抑制效果與劑量正相關(guān),其作用可能通過(guò)抑制VEGF表達(dá)實(shí)現(xiàn)。
[Abstract]:Objective to investigate the effect of celecoxib on retinal neovascularization in OIR by injecting celecoxib into vitreous cavity of Oxygen-induced retinopathy (OIR) model in rats. Methods Ninety-six 7-day-old SD neonatal rats were randomly divided into 6 groups: control group (n = 6): control group (n = 10), group A (n = 10), control group (n = 5), group B, n = 5 渭 g, group C, n = 20 渭 g, group D, n = 80 渭 g, respectively. OIR model was established in all groups except group Z in normal environment. The neonatal rats were given intravitreous injection of DMSO and celecoxib at the same dose on the 12th day after birth, and were killed on the 17th day after birth. The morphology of retinal tissue was observed by HE staining and the number of vascular endothelial nuclei breaking through the inner boundary membrane was counted. The expression of VEGF protein was detected by immunohistochemical staining in paraffin sections. Results HE staining showed that the number of vascular endothelial nuclei breaking through the membrane of retina was 0.44 鹵0.18, 30.60 鹵5.36), 19.58 鹵4.58) and 7.58 鹵2.68, respectively, in group A and B, with the exception of group O and group A, the number of vascular endothelial nuclei in group D was 7.58 鹵2.68, and that in group B was 7.58 鹵2.68, with the exception of group O and group A, which were 28.05 鹵4.68 and 10.13 鹵1.93, respectively. After celecoxib treatment, the number of vascular endothelial nuclei which broke through the inner boundary membrane decreased significantly and was positively correlated with the dose, the immunohistochemical results showed that the expression of VEGF protein was negative in group Z. The positive expression rate of VEGF protein in group A was higher than that in group C (P < 0.05). The positive rate of VEGF protein in group A was 900.The positive rate was higher than that in group B and C respectively, and the positive expression of VEGF protein in group C was decreased to 6842G and 30mg / kg in the latter three groups respectively, and the positive rate was higher than that in group C (P < 0.05), and the positive expression of VEGF protein in group A was significantly higher than that in group C (P < 0.05). Conclusion Celecoxib can effectively inhibit the growth of retinal neovascularization in rat OIR model, and the inhibitory effect is positively correlated with the dose, which may be achieved by inhibiting the expression of VEGF.
【學(xué)位授予單位】：石河子大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R774.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李松峰;鄧光達(dá);劉敬花;馬燕;盧海;;玻璃體內(nèi)注射雷珠單抗治療早產(chǎn)兒視網(wǎng)膜病變[J];眼科新進(jìn)展;2016年07期

2 Saman Nassiri;Gholamreza Houshmand;Mostafa Feghhi;Alireza Kheirollah;Mohammad Bahadoram;Nariman Nassiri;;Effect of periocular injection of celecoxib and propranolol on ocular level of vascular endothelial growth factor in a diabetic mouse model[J];International Journal of Ophthalmology;2016年06期

3 李丹;董宇;;早產(chǎn)兒視網(wǎng)膜病變發(fā)病基礎(chǔ)及抗VEGF藥物治療研究進(jìn)展[J];眼科新進(jìn)展;2016年04期

4 張，

本文編號(hào)：1809554